BIOGEN INC (BIIB) Fundamental Analysis & Valuation

NASDAQ:BIIB • US09062X1037

189.13 USD
+0.89 (+0.47%)
Last: Mar 10, 2026, 02:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BIIB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 519 industry peers in the Biotechnology industry. BIIB gets an excellent profitability rating and is at the same time showing great financial health properties. BIIB is valued quite cheap, but it does not seem to be growing. These ratings would make BIIB suitable for value investing!


Dividend Valuation Growth Profitability Health

7

1. BIIB Profitability Analysis

1.1 Basic Checks

  • In the past year BIIB was profitable.
  • BIIB had a positive operating cash flow in the past year.
  • Each year in the past 5 years BIIB has been profitable.
  • In the past 5 years BIIB always reported a positive cash flow from operatings.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 4.39%, BIIB belongs to the top of the industry, outperforming 90.56% of the companies in the same industry.
  • BIIB has a better Return On Equity (7.08%) than 91.33% of its industry peers.
  • With an excellent Return On Invested Capital value of 8.93%, BIIB belongs to the best of the industry, outperforming 93.26% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for BIIB is significantly below the industry average of 19.44%.
  • The last Return On Invested Capital (8.93%) for BIIB is above the 3 year average (8.93%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • BIIB has a better Profit Margin (13.07%) than 92.10% of its industry peers.
  • In the last couple of years the Profit Margin of BIIB has declined.
  • BIIB's Operating Margin of 27.94% is amongst the best of the industry. BIIB outperforms 96.34% of its industry peers.
  • In the last couple of years the Operating Margin of BIIB has declined.
  • BIIB's Gross Margin of 75.69% is amongst the best of the industry. BIIB outperforms 83.62% of its industry peers.
  • In the last couple of years the Gross Margin of BIIB has declined.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BIIB Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
  • BIIB has more shares outstanding than it did 1 year ago.
  • BIIB has less shares outstanding than it did 5 years ago.
  • BIIB has a better debt/assets ratio than last year.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.33 indicates that BIIB is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.33, BIIB is in the better half of the industry, outperforming 67.63% of the companies in the same industry.
  • BIIB has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as BIIB would need 3.11 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.11, BIIB belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
  • A Debt/Equity ratio of 0.34 indicates that BIIB is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.34, BIIB is not doing good in the industry: 68.21% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.33
ROIC/WACC1.06
WACC8.45%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.68 indicates that BIIB has no problem at all paying its short term obligations.
  • BIIB's Current ratio of 2.68 is on the low side compared to the rest of the industry. BIIB is outperformed by 68.59% of its industry peers.
  • A Quick Ratio of 2.03 indicates that BIIB has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.03, BIIB is doing worse than 74.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. BIIB Growth Analysis

3.1 Past

  • The earnings per share for BIIB have decreased by -7.16% in the last year.
  • The earnings per share for BIIB have been decreasing by -14.17% on average. This is quite bad
  • The Revenue has been growing slightly by 2.22% in the past year.
  • The Revenue has been decreasing by -5.96% on average over the past years.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.53% yearly.
  • The Revenue is expected to decrease by -0.48% on average over the next years.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. BIIB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 12.37, which indicates a correct valuation of BIIB.
  • BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 96.15% of the companies in the same industry.
  • BIIB is valuated cheaply when we compare the Price/Earnings ratio to 26.45, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 11.76 indicates a reasonable valuation of BIIB.
  • BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.30% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.65. BIIB is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.37
Fwd PE 11.76
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaper than 97.30% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BIIB is valued cheaply inside the industry as 97.50% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.75
EV/EBITDA 8.27
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIIB does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)2.4
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIIB Dividend Analysis

5.1 Amount

  • BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIIB Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

NASDAQ:BIIB (3/10/2026, 2:23:07 PM)

189.13

+0.89 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners97.35%
Inst Owner Change5.37%
Ins Owners0.16%
Ins Owner Change7.93%
Market Cap27.76B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target210.39 (11.24%)
Short Float %3.1%
Short Ratio2.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)7.72%
PT rev (3m)15.94%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)5.69%
EPS NY rev (3m)4.68%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE 12.37
Fwd PE 11.76
P/S 2.81
P/FCF 13.75
P/OCF 12.59
P/B 1.52
P/tB 10.73
EV/EBITDA 8.27
EPS(TTM)15.29
EY8.08%
EPS(NY)16.08
Fwd EY8.5%
FCF(TTM)13.76
FCFY7.27%
OCF(TTM)15.02
OCFY7.94%
SpS67.39
BVpS124.4
TBVpS17.63
PEG (NY)2.4
PEG (5Y)N/A
Graham Number206.87
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.33
F-Score4
WACC8.45%
ROIC/WACC1.06
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / BIIB FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


How profitable is BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a profitability rating of 7 / 10.


How financially healthy is BIOGEN INC?

The financial health rating of BIOGEN INC (BIIB) is 7 / 10.